187 related articles for article (PubMed ID: 20375816)
1. European Network of Gynaecological Oncological Trial Groups' requirements for trials between academic groups and pharmaceutical companies.
Vergote I; Pujade-Lauraine E; Pignata S; Kristensen GB; Ledermann J; Casado A; Sehouli J; Mirza M; Fossati R; Marth C; Creutzberg C; Del Campo J; Siddiqui N; Calvert P; Bamias A; Tulunay G; van der Zee AG; du Bois A;
Int J Gynecol Cancer; 2010 Apr; 20(3):476-8. PubMed ID: 20375816
[No Abstract] [Full Text] [Related]
2. European Network of Gynaecological Oncological Trial Groups' Requirements for Trials Between Academic Groups and Industry Partners--First Update 2015.
du Bois A; Reuss A; Pujade-Lauraine E; Pignata S; Ledermann J; Casado A; Sehouli J; Mirza M; Colombo N; Marth C; Witteveen E; Del Campo J; Calvert P; Aravantinos G; Vardar MA; van der Zee AG; Korach J; Taskiran C; Fehr M; Glasspool R; Pfisterer J; Cibula D; Vergote I;
Int J Gynecol Cancer; 2015 Sep; 25(7):1328-30. PubMed ID: 26067859
[TBL] [Abstract][Full Text] [Related]
3. The European Network for Gynaecological Oncological Trial Groups Charta for Privileged Partnership.
Marth C; du Bois A; Schauer C; du Bois A; Casado A; Vergote I; del Campo JM; Goudopoulou A; Pujade-Lauraine E; Bruchim I; Colombo N; Pignata S; Ledermann J; Chekerov R; Raza Mirza M; Westermann A; Glasspool R; Taskiran C; Fehr M; Cibula D
Int J Gynecol Cancer; 2015 Jul; 25(6):1094-5. PubMed ID: 26098090
[No Abstract] [Full Text] [Related]
4. European Network of Gynaecological Oncological Trial Groups' requirements for trials between academic groups and industry partners - a new Model D for drug and medical device development.
Concin N; Ray-Coquard I; Glasspool RM; Braicu E; Farrelly L; Votan B; Mirza MR; Gonzalez Martin A; Vergote I; Pignata S
Int J Gynecol Cancer; 2020 Jun; 30(6):730-734. PubMed ID: 32404377
[No Abstract] [Full Text] [Related]
5. Joint ENGOT and GOG Foundation requirements for trials with industry partners.
Vergote I; Coleman RL; Pignata S; Bookman MA; Marth C; Herzog TJ; Gonzalez Martin A; Copeland LJ;
Int J Gynecol Cancer; 2019 Sep; 29(7):1094-1097. PubMed ID: 31320391
[No Abstract] [Full Text] [Related]
6. Roadmap for the European Network of Gynaecological Trial groups (ENGOT) Trials.
Vergote I; Elser G; Votan B; Farrelly L; De Roover J; Bryce J; du Bois A;
Int J Gynecol Cancer; 2013 Sep; 23(7):1339-43. PubMed ID: 23970159
[TBL] [Abstract][Full Text] [Related]
7. Clinical Centers of Excellence. Gynecologic oncology.
Med Econ; 2009 Feb; 86(4):21. PubMed ID: 19405371
[No Abstract] [Full Text] [Related]
8. Society of Gynecologic Oncology meeting highlights progress.
Jenks S
J Natl Cancer Inst; 2011 Apr; 103(7):533-4. PubMed ID: 21436060
[No Abstract] [Full Text] [Related]
9. Clinical centers of Excellence. Gynecologic oncology. Yale cancer center.
Bendix J
Med Econ; 2009 Feb; 86(4):29. PubMed ID: 19405375
[No Abstract] [Full Text] [Related]
10. Clinical Centers of Excellence. Gynecologic oncology. Duke University Medical Center.
Aungst H
Med Econ; 2009 Feb; 86(4):24. PubMed ID: 19405372
[No Abstract] [Full Text] [Related]
11. The pharmaceutical industry and oncology in central and eastern Europe.
Ben-Am M; Gemperli B; Covelli A; Burke G
Ann Oncol; 1999; 10 Suppl 6():15-7. PubMed ID: 10676548
[TBL] [Abstract][Full Text] [Related]
12. Clinical Center of Excellence. Gynecologic oncology. Cedars-Sinai medical center.
Brower A
Med Econ; 2009 Feb; 86(4):28. PubMed ID: 19405374
[No Abstract] [Full Text] [Related]
13. Clinical Centers of Excellence. Gynecologic oncology. University of Texas M.D. Anderson cancer center.
Bennett D
Med Econ; 2009 Feb; 86(4):26. PubMed ID: 19405373
[No Abstract] [Full Text] [Related]
14. Harmful impact of EU clinical trials directive.
Hemminki A; Kellokumpu-Lehtinen PL
BMJ; 2006 Mar; 332(7540):501-2. PubMed ID: 16513690
[No Abstract] [Full Text] [Related]
15. Joint ENGOT and GOG Foundation requirements for trials with industry partners.
Vergote I; Coleman RL; Pignata S; Bookman MA; Marth C; Herzog TJ; Gonzalez-Martin A; Copeland LJ; ;
Gynecol Oncol; 2019 Aug; 154(2):255-258. PubMed ID: 31331494
[No Abstract] [Full Text] [Related]
16. Good clinical practice is now obligatory in academic clinical drug research in the European Union.
Jørgensen A; Bach KF; Friis K
Basic Clin Pharmacol Toxicol; 2004 Feb; 94(2):57-8. PubMed ID: 14748847
[TBL] [Abstract][Full Text] [Related]
17. EU directive on clinical trials penalizes small sponsors.
Meldolesi A
Nat Biotechnol; 2003 Aug; 21(8):838. PubMed ID: 12894186
[No Abstract] [Full Text] [Related]
18. Registering clinical trials in India.
Bhatt A; Sewlikar S
Natl Med J India; 2006; 19(1):1-3. PubMed ID: 16570676
[No Abstract] [Full Text] [Related]
19. Performing phase I clinical trials of anticancer agents: perspectives from within the European union and Japan.
Forster MD; Saijo N; Seymour L; Calvert H
Clin Cancer Res; 2010 Mar; 16(6):1737-44. PubMed ID: 20215555
[TBL] [Abstract][Full Text] [Related]
20. Barriers to clinical trials vary according to the type of trial and the institution.
Govindarajan R; Young JW; Harless CL; Hutchins LF
J Clin Oncol; 2007 Apr; 25(12):1633-4; author reply 1634. PubMed ID: 17443010
[No Abstract] [Full Text] [Related]
[Next] [New Search]
